Silo Pharma Strengthens Global IP Portfolio With Japanese Patent Allowance For SPC-15 Post-Traumatic Stress Disorder (PTSD) Therapy

Silo Pharma, Inc., a developmental-stage biopharmaceutical company focused on innovative drug formulations and delivery technologies, announced that the Japan Patent Office has issued a Notice of Allowance for a patent application covering its lead candidate, SPC-15. The therapy is a novel intranasal treatment being developed for post-traumatic stress disorder (PTSD).

The patent application, titled “Compositions and Methods for the Prevention of Stress-Induced Fear, Depression-Like Behaviour, and Anxiety-Like Behaviour,” expands the company’s intellectual property portfolio in the field of stress-related disorders. It supports Silo’s broader strategy of securing protection for its proprietary therapeutic approaches in major global markets, particularly in stress-modulating treatments.

“The approval of this patent is extremely important to Silo as it protects our lead asset while simultaneously bolstering our intellectual property portfolio, said Eric Weisblum, Chief Executive Officer of Silo Therapeutics. “Additionally, it reinforces the novelty of our approach to preventing stress-induced behavioral disorders and expands our international patent estate in a highly significant pharmaceutical jurisdiction.”

A Notice of Allowance means that the patent office has completed its review and determined the application satisfies patentability requirements, with a formal grant expected soon. The approved claims cover both composition and method aspects of SPC-15, including innovative therapeutic strategies designed to prevent or reduce behavioural effects linked to stress, fear, anxiety, and depressive symptoms.